guanosine 3',5'-monophosphate (cGMP) might be useful markers for screening. Objective-To compare directly the power of the three immunoreactive forms of ANP (CT-ANP,f3-ANP, NT-ANP) and BNP and cGMP to detect asymptomatic left ventricular dysfunction. Methods and results-Radionuclide ventriculography was used to study left ventricular ejection fraction in 37 patients with asymptomatic left ventricular dysfunction, 32 patients with mild to moderate congestive heart failure, and 38 controls. CT-ANP, NT-ANP, P-ANP, BNP, and cGMP were measured at rest and 3 minutes after exercise. Plasma BNP was the most sensitive marker for patients with asymptomatic left ventricular dysfunction but it reached only a sensitivity of 58% and a specificity of 76% at rest and a sensitivity of 65% and a specificity of 84% after exercise. Combined measurements of all natriuretic peptides and cGMP did not [1] [2] [3] ANP maintains sodium homoeostasis by natriuresis and diuresis. ANP also acts as a vasodilator and as an antagonist of the renin angiotensin system under normal conditions. It is stored in the atrial wall as a 126 amino acid pro-ANP molecule. In response to atrial stretch immunoreactive products from the N-terminal part (NT-ANP, amino acid 1-98) and from the C-terminal part (CT-ANP, amino acid 99-126) appear in the plasma.45 Additionally a dimer form of CT-ANP (,B-ANP) can be found.6 Brain natriuretic peptide (BNP) is a 32 amino acid peptide with a high degree of structural homology with ANP. BNP has the same main biological actions as ANP but it is mainly secreted from the ventricle.78 Cyclic guanosine 3'5'-monophosphate (cGMP) acts as a second messenger for ANP and BNP in the target cells. In response to increased secretion of ANP and BNP from the heart, cGMP is released from the target cells and this raises plasma cGMP concentrations.9 11 Heart failure can be the end point of various diseases such as myocardial damage caused by myocardial infarction, primary or secondary dilated cardiomyopathy, or valvar disease. 12 13 It has become evident that haemodynamic and neuroendocrine factors participate in the pathophysiology of chronic heart failure. Immunoreactive C-terminal and N-terminal cleavage products of pro-ANP as well as ,-ANP are raised in the plasma of patients with congestive heart failure because of enhanced production and release from the atria, additional secretion from the ventricle, and reduced clearance in the liver and the kidneys. Circulating BNP and cGMP are also raised in patients with congestive heart failure.'4 16 The extent of the increase in natriuretic peptides is of prognostic value in congestive heart failure. '7 19 There is also some evidence that natriuretic peptides are of independent prognostic significance after myocardial infarction. 20 Natriuretic peptides may also serve as markers for asymptomatic left ventricular (LV) dysfunction. The importance of early identification of patients with asymptomatic left ventricular dysfunction is evident from the results of the SOLVD study.21 Early treatment with the angiotensin converting enzyme (ACE) inhibitor enalapril prevented or retarded the development of heart failure in patients with left ventricular ejection fraction (LVEF) < 35 % and no clinical signs of heart failure.
Recent studies have focused on the role of natriuretic peptides as markers for asymptomatic left ventricular dysfunction.22 24 These studies were carried out for different natriuretic peptides, measured in different study populations and the results were partly con-flicting. Our study adds important information to these data and may explain some of the existing discrepancies. The main purpose of our study was to compare the power of CT-ANP, ,B3ANP, NT-ANP, BNP, and cGMP in detecting asymptomatic left ventricular dysfunction. We also studied whether post-stress measurements or combined measurements improved the detection of patients with asymptomatic left ventricular dysfunction.
Patients and methods

STUDY POPULATION
We prospectively studied consecutive subjects between September 1993 and June 1994, who were referred for rest and exercise radionuclide ventriculography at the Centre for Cardiac Rehabilitation Grossgmain. Only patients in sinus rhythm and without frequent supraventricular and ventricular beats were included in the study. They all had normal renal (serum creatinine < 106,mol/l) and normal hepatic function. Patients with hypertension who responded poorly to treatment, those with haemodynamically relevant valvar disease, and patients with peripheral artery disease were excluded from the study. A total of 107 subjects entered the study (83 men and 24 women; mean age 58-9 (range 25-78). Coronary artery disease had been diagnosed in more than half those in each study group. In total 78 (72 9%) participants had confirmed coronary artery disease and 64 (60%) had had at least one myocardial infarction, which had been diagnosed by electrocardiographic criteria and an increase in serum enzymes. Patients entered the study no earlier than 10 weeks after myocardial infarction. Five Blood was collected in prechilled tubes containing EDTA (ethylendiamine-tetraacetic acid 1-5 g/l) and immediately centrifuged at 4°C at 3000 rpm for 10 minutes before the plasma was frozen at -30°C until measurement, which was carried out within one month after blood collection.
Plasma concentrations of CT-ANP, B-ANP, NT-ANP, and BNP were measured by commercially available radioimmunoassays (RIK 8798, 9105, 9129 , and 9086, Peninsula Laboratories, Belmont, CA, USA).23 26 In brief, 1 ml (ANPs) and 2 ml (BNP) of plasma were acidified with equal volumes of 0 1% trifluoroacetic acid and the acidified plasma was applied to a C18 cartridge (Sep column 1, Peninsula) for extraction of peptides from plasma after cartridges were pre-activated by washing with 60% acetonitrile in 0 1% trifluoroacetic acid. After washing with of 0-1% trifluoroacetic acid, peptides were eluted with 60% acetonitrile in 0-1% trifluoroacetic acid. The eluant was evaporated to dryness in a centrifugal vacuum concentrator. The residue was resuspended in assay buffer and peptides were assayed according to the Peninsula Laboratories protocol. The mean recoveries through the extraction process were 82% (CT-ANP), 71% (,BANP), 67% (NT-ANP), and 84% (BNP). Natriuretic peptide concentrations given in the text were not corrected for recovery. The detection limits were lpg/tube for all four assays. The intra-assay coefficients of variation were 7-3% (CT-ANP), 6-1% (-ANP), 4-3% (NT-ANP), and 8-5% (BNP).
The inter-assay coefficients of variation were 11-2% (CT-ANP), 12-5% (,B3ANP), 10-3%
(NT-ANP)l, and 10-5% (BNP). Plasma cGMP was measured after plasma ethanol extraction. We added 1 ml ethanol to 250 ,l of plasma, mixed it, and centrifuged it for 15 minutes and collected the supernatant.
The precipitate was washed with 500 pl of ethanol and centrifuged for 15 minutes again. The supematants were combined and evaporated to dryness at 56°C under a stream of nitrogen. The average recovery of the extraction procedure was 99-8%. The residues were redissolved in 1 ml assay buffer and 500 ul was then used in the assay for acetylation. Immunoreactive cGMP was measured with a 125I-labelled radioimmunoassay (cGMP-assay RPA 525; Amersham International, Amersham, Buckinghamshire). The upper limit of the reference interval using this procedure is 6'6 nmol/l and the intra and inter assay coefficients of variation were 6&4% and 9-2%, respectively. I Plasma creatinine concentrations were determined enzymatically with reagents group in table 1. There was no significant difference between the three groups in mean body mass index. Mean age was similar in the NYHA I group (57-6 years) and the controls (57 5 years). The mean age of the NYHA II patients (62'1 years) was significantly higher than that of the controls. Prevalence of coronary artery diseases (CAD), myocardial infarction (MI), and treated hypertension among patients and controls as well as drug treatments are shown in table 1. There was no statistically significant difference between NYHA I patients and controls in the prevalence of CAD, MI, and hypertension.
LVEF, PFR, blood pressure, and maximal work loads are compared in table 2. All these variables were significantly different in symptomatic patients and controls except for blood pressure during rest. The comparison of asymptomatic patients with LV dysfunction with controls showed significantly lower LVEF during rest (P < 0001) and stress (P < 0 001) and significantly lower PFR during rest (P < 0001) and stress (P = 0 030) in asymptomatic patients. In contrast to these highly significant differences there was no significant difference in maximal workload.
Within the control group and the group of patients with symptomless left ventricular dysfunction no significant correlation between left ventricular ejection fraction and circulating natriuretic peptides and cGMP was found. However, in the group of patients with symptomatic heart failure (n = 32), LVEF was significantly inversely correlated with CT-ANP (r = -054, P = 0002), NT-ANP (r = Spearman correlation coefficients r are given in the upper line and significance levels P at 95% confidence intervals are given below.
-052, P = 0002) and BNP (r = -061, P < 0001). The lack of correlation of natriuretic peptides among patients with asymptomatic LV dysfunction and significant for BNP correlation among symptomatic patients is shown in fig 1. Mean plasma concentrations for all natriuretic peptides and for cGMP significantly increased during exercise among controls, NYHA class I patients, and NYHA class II patients. In table 3 mean values (SD) for circulating natriuretic peptides and cGMP of the control group are compared with those in patients with NYHA class I and NYHA class II disease. The group of patients with symptomatic left ventricular dysfunction (NYHA class II) had significantly higher concentrations for all natriuretic peptides and cGMP than the control group. These significant differences were observed at rest as well as poststress. For patients with symptomless left ventricular dysfunction (NYHA class I) plasma concentrations of all peptides and cGMP were higher than in the controls, again both at rest and post-stress. However, the difference was statistically significant only for BNP (rest measurement P = 0004 and poststress measurement P = 0004).
We looked for correlations between the natriuretic peptides and cGMP in the controls and in NYHA class I and NYHA class II patients at rest and after exercise. For each peptide and for cGMP, plasma concentrations at rest correlated highly significantly with poststress measurements with correlation coefficients ranging from r = 061 for CT-ANP in the control group to r = 089 for BNP in the NYHA II group (data not shown). Within the three groups significant correlations of CT-ANP, fANP, and NT-ANP with each other were found at rest and after exercise. Differences in BNP between controls and NYHA I patients were sought by comparing correlation coefficients between BNP, NT-ANP, and cGMP in controls and symptomless patients ( 
1-Specificity
To compare the ability of natrii tides and cGMP to correctly classi into groups with normal and reduce tricular function (NYHA class I' structed ROC plots27 for rest ( fig   stress measurements (fig 2B) We also studied the ability of natriuretic peptide and cGMP concentrations to correctly identify patients with a resting ejection fraction below 35%, regardless of their NYHA classification. Sixteen of 107 study participants had a LVEF < 35%. ROC blot analysis showed that CT-ANP had the best discriminative power for with a sensitivity of 0-81, a specificity of 0-88, a positive predictive value of 0-54, a negative predictive value of 0-96, Several studies have shown that natriuretic peptides are significantly raised in symptouretic pep-matic congestive heart failure. This was conify subjects firmed by the present study for CT-ANP, ed left ven-,B-ANP, NT-ANP, BNP, and cGMP by comwe con-paring patients in NYHA class II with a con-2A) and trol group. We also found significant area under correlations between left ventricular ejection ar compar-fraction and plasma concentrations of BNP, r investiga-NT-ANP, and CT-ANP in patients with at rest and symptomatic LV dysfunction, with the corre-!P, ,B-ANP, lation being strongest for BNP. This accords from 0 53 with recent reports by Choy et a129 and 06) for rest Motwani et al. 24 Both groups found better corercise BNP relations between LVEF and BNP than r between between LVEF and ANP. n the other Our study concentrated on the power of r-ANP, ,-natriuretic peptides to identify patients with vere no sig-symptomless left ventricular dysfunction, because these patients could benefit from early treatment with ACE inhibitors. Comparatively few and partly conflicting data are available regarding this question. Winters et al5 showed that immunoreactive parts of the N-terminal ANP could discriminate a group of five patients classified as NYHA I from normal controls. In a substudy of the SOLVD investigation Francis et al22 found significantly raised concentrations of ANP in patients with an LVEF of 35% or less but without overt congestive heart failure. In a recent publication Lerman et al23 reported that NT-ANP is an excellent marker for early identification of patients with symptomless heart failure, with high sensitivity (90%) and specificity (92%). Choy et al studied 75 survivors of a recent myocardial infarction to see whether patients with a LVEF < 40% could be identified by clinical assessment, echocardiography, or measurement of ANP and BNP. Measurement of plasma BNP concentrations reached a sensitivity (84%), similar to that of qualitative visual assessment echocardiography (82%). Plasma ANP concentration was less sensitive (64%) . 29 One of the main goals of our study was to define a control group and a group of symptomless patients as accurately as possible. In contrast to the studies mentioned above our study gives a more precise definition of symptomless patients with left ventricular dysfunction. As well as reporting no signs of congestive heart failure in response to detailed questioning, our NYHA I patients showed no significant difference in the mean maximal work load compared with controls. Our definition of normal LVEF was above 55% at rest or above 65% at peak exercise. Although the definition of normal left ventricular ejection fraction measured by radionuclide ventriculography shows considerable variation between different laboratories, we can assume that our cutoff value for normal LVEF lies above those chosen in the other reports. On the basis of our definition of left ventricular dysfunction, patients in NYHA class I had higher plasma concentrations of CT-ANP, ,-ANP, NT-ANP, BNP, and cGMP than the controls. However, only BNP was significantly higher in patients in NYHA class I than in the controls and therefore was a better discriminator for asymptomatic LV dysfunction than the immunoreactive C-terminal and N-terminal parts of ANP. This finding accords with that of Choy et al. 29 Our findings do not confirm the results of Lerman et al,'3 who found that NT-ANP was a powerful marker for patients with symptomless LV dysfunction. In our study neither CT-ANP nor NT-ANP were suitable for detecting asymptomatic LV dysfunction. A possible explanation for the differing results might be differences in selection criteria used for NYHA classification. Lerman et al did not compare maximal work load in the NYHA I patients and controls. Furthermore the predictive power of ANP and BNP for asymptomatic LV dysfunction cannot be compared because BNP was not measured by Lerman et al. In our study, although cGMP is a second messenger for BNP, it could not discriminate between NYHA I patients and controls at rest and 3 minutes after exercise. This confirms our previous results with cGMP. However, in an earlier study we showed that cGMP was a marker for symptomless left ventricular dysfunction when measured 30 minutes after ergometric exercise.26 Because natriuretic peptides are known to have very short half lives we did not carry out late measurements in the present study.
For correlations between natriuretic peptides and cGMP there was a clear difference between NYHA class I patients and controls in terms of BNP relations. At rest as well as post-stress BNP did not correlate with NT-ANP in the control group. However, BNP and NT-ANP were highly correlated in the group containing NYHA I patients. This observation might reflect a relation between atrial and ventricular dysfunction in mild heart failure. This difference and the fact that BNP was the best marker for symptomless left ventricular dysfunction in our study may reflect the different sites of secretion of BNP and ANP. BNP is mainly secreted from the ventricle, whereas ANP is primarily secreted from the atrium. An additional secretion of ANP from the left ventricle in addition to the atrium has been reported in severe congestive heart failure.30 Secretion of ANP from the ventricle might not have influenced the results of our study, because our study population did not contain patients in NYHA classes III and IV. Post-stress measurements and combined measurements based on an CHAID algorithm, which was carried out in our study, extended the usefulness of previously available data. However, this approach did not add important information to rest measurement and might not justify cost and effort in routine diagnosis.
We also studied the ability of natriuretic peptides and cGMP to identify patients with markedly impaired LVEF. By doing so we did not apply our criteria for asymptomatic left ventricular dysfunction because most of these patients (LVEF < 35%) were symptomatic. As we did for NYHA I patients we used ROC plot analysis to study the efficiency of these factors to correctly pick up patients with a LVEF < 35% in our sample. With this approach we obtained similar results for NT-ANP, CT-ANP, BNP, and cGMP, the sensitivity (0-81) and the specificity (0-88) tended to be highest for CT-ANP ( fig 2C) . The predictive performance of ,B-ANP was significantly lower. Wei et al6 found that ,B-ANP was highly specific for the diagnosis of heart failure. Our results differ from their results. The reason for this discrepancy might be that the study of Wei et al6 mainly contained patients with severe congestive heart failure and this might greatly have influenced the result.
We suggest that natriuretic peptides and cGMP measured at rest and post-stress have a low diagnostic yield for screening purposes. Our observations are supported by the work of Chaidhal et al"3 and Wallen et al. 32 These two studies investigated atrial natriuretic pep-tide concentrations in samples drawn from the general population. Both studies accord with our suggestion that the plasma concentrations of natriuretic peptides in an individual do not have sufficient predictive value for asymptomatic heart failure to justify their use in population screening.
Limitations of our study The control group was primarily defined on the basis of LVEF. Because radionuclide ventriculography studies in normal volunteers were not possible for ethical reasons we studied patients with coronary artery disease with preserved LV function. This was also the case in the study by Lerman et al. 23 We used Doppler echocardiography to exclude LV diastolic dysfunction in the control group. To compare diastolic function in controls, NYHA I, and NYHA II patients we used the PFR derived from equlibrium ventriculography. We must stress that PFR was calculated from 16 frame aquisition data which might not be sufficient to obtain an accurate absolute measure of diastolic function. In our study it was used to rule out major differences in diastolic function between the study groups. In all groups, PFR correlated with LVEF.
More study participants in the NYHA I and NYHA II group were taking ,B blockers, calcium channel blockers, ACE inhibitors, diuretics, digitalis, and nitrates than in the control group. Because of the variety of drugs that were taken at different doses in comparatively small numbers of patients and controls we did not carry out multivariate analysis using treatment as a covariate. Potential confounding effects of treatment cannot be excluded.
CONCLUSIONS
Our study confirmed that natriuretic peptide secretion was increased in patients with symptomatic and symptomless left ventricular dysfunction. BNP was a better marker for symptomless LV dysfunction than CT-ANP, ,B-ANP, NT-ANP, and cGMP. In our sample natriuretic peptides and cGMP identified patients with markedly impaired LVEF (< 35%), but we must stress that most of these patients had symptoms. However, even with BNP the sensitivity and specificity were not sufficiently high for screening large populations for symptomless left ventricular dysfunction. Post-stress measurements and combined measurements did not add substantially to the information provided by a single measurement at rest. Our data suggest that of all the natriuretic peptides and cGMP, BNP is the best marker for symptomless LV dysfunction when measured at rest or 3 minutes after exercise.
But its relatively low sensitivity and specificity for the detection of completely symptomless patients might limit the use of BNP measurements for a wide routine screening for symptomless left ventricular dysfunction. It could, however, be helpful in monitoring treatment in patients with poor echocardiographic images.
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